NIH SBIR Phase I Guide: How to Win Your First NIH Small Business Award

NIH SBIR: The Largest Biomedical Innovation Funder

The National Institutes of Health spends roughly $1.2 billion annually on SBIR and STTR awards, making it the single largest source of non-dilutive seed funding for biomedical small businesses in the world. That figure is spread across 24 institutes and centers (ICs), each with its own scientific priorities, program officers, and funding behavior. If you are building a health technology company — diagnostics, therapeutics, medical devices, digital health tools, or research instrumentation — NIH SBIR Phase I is likely the highest-value funding mechanism available to you.

Phase I awards provide up to $275,000 in direct costs over a six- to twelve-month project period. The purpose is narrow and specific: demonstrate the scientific and technical feasibility of your proposed innovation. You are not building a finished product. You are generating enough evidence that your concept works to justify a Phase II investment of up to $1.75 million.

NIH SBIR differs from other agency SBIR programs in fundamental ways. Review is conducted by scientific study sections — the same peer review infrastructure used for R01s and other investigator-initiated grants. Scoring follows the five standard NIH review criteria. Proposals are judged primarily on scientific merit and health impact, not on alignment with a pre-defined topic area. This makes NIH SBIR uniquely suited to investigator-driven innovations that address unmet medical needs, even when those innovations do not fit neatly into another agency's solicitation topics.

The funding rate varies by institute but typically falls between 15% and 25% for Phase I. That is substantially higher than R01 success rates at most ICs. For a well-prepared small business with genuine innovation, these are reasonable odds — and the downstream value of a Phase I award extends well beyond the $275,000. It signals NIH validation to investors, strategic partners, and future grant reviewers.

For current NIH SBIR opportunities, browse the SBIR grants on Granted.

Finding the Right NIH Institute

NIH is not a monolithic agency. It is 24 distinct institutes and centers, each funding research in its own therapeutic area or scientific domain. Submitting to the wrong IC is one of the most common mistakes first-time NIH SBIR applicants make — and it can mean the difference between a study section that understands your technology and one that does not.

The major ICs and their focus areas most relevant to SBIR applicants:

• NCI (National Cancer Institute) — oncology diagnostics, therapeutics, screening technologies, cancer data science
• NHLBI (Heart, Lung, and Blood) — cardiovascular devices, pulmonary therapeutics, hematology tools
• NIAID (Allergy and Infectious Diseases) — vaccines, antimicrobials, immune diagnostics, pandemic preparedness
• NIMH (Mental Health) — digital mental health tools, neuropsychiatric diagnostics, behavioral interventions
• NINDS (Neurological Disorders and Stroke) — neurotechnology, stroke rehabilitation, neurodegenerative disease tools
• NIDDK (Diabetes and Digestive and Kidney Diseases) — diabetes management devices, GI diagnostics, renal technologies
• NIBIB (Biomedical Imaging and Bioengineering) — imaging platforms, biosensors, point-of-care devices, computational tools
• NCATS (Advancing Translational Sciences) — drug repurposing platforms, clinical trial tools, rare disease technologies

Start your institute identification by searching NIH RePORTER (reporter.nih.gov) for funded SBIR projects similar to yours. Filter by activity code (R43 for SBIR Phase I, R44 for Phase II) and look at which ICs funded those projects. If you find three or four funded projects that overlap with your technology and they were all funded by NIBIB, that is a strong signal.

Contact the SBIR program officer at your target IC before you submit. This is not optional advice — it is a strategic necessity. Program officers can tell you whether your technology aligns with the IC's current priorities, whether a directed funding opportunity might be a better fit than the Omnibus, and which study section is likely to review your application. A fifteen-minute phone call can save you months of misdirected effort.

Omnibus Solicitation vs. Directed Topics

NIH SBIR operates through two parallel solicitation tracks, and understanding the difference is critical to your submission strategy.

The Omnibus Solicitation (PA-25-XXX series) is NIH's standing, open-ended SBIR/STTR solicitation. It accepts applications on any health-related topic within the mission of any participating IC. There are no pre-defined technical topics. You propose whatever innovation you believe has scientific merit and commercial potential. Receipt dates occur three times per year (typically January, April, and September). The Omnibus is the right vehicle when your innovation is broadly applicable, when it does not fit a specific directed topic, or when you want maximum flexibility in defining your project scope.

Directed Funding Opportunity Announcements (FOAs) target specific technical areas that an IC has identified as high priority. Examples include directed topics in antimicrobial resistance diagnostics (NIAID), AI-enabled clinical decision support (NCI), or point-of-care devices for low-resource settings (NIBIB). Directed FOAs often have dedicated funding set aside, which can mean less competition for that specific pool of money. They also signal exactly what the IC wants to fund, which gives you a clearer target for framing your proposal.

The strategic calculus: if a directed FOA closely matches your technology, apply to it. The alignment between your innovation and the IC's stated need reduces reviewer guesswork about significance. If no directed FOA fits well, the Omnibus is your path. Do not force-fit your technology into a directed topic where the match is weak — reviewers will notice, and you will score poorly on significance.

Check the NIH Guide for Grants and Contracts (grants.nih.gov/funding/searchguide) regularly for new directed FOAs. Many have a single receipt date, and the window between publication and deadline can be as short as three months.

Writing Your Specific Aims Page

The Specific Aims page is the single most consequential page of your NIH SBIR application. Study section members who are not assigned as primary or secondary reviewers will often read only this page before the discussion. If your Specific Aims page does not make a compelling case, the rest of your application may never be read.

For SBIR, the Specific Aims page must accomplish something that R01 Specific Aims pages do not: it must communicate both scientific merit and commercial relevance in a single page. Reviewers are evaluating your proposal as a business proposition for taxpayer-funded innovation, not solely as a scientific investigation.

Opening paragraph: The problem and the gap. Lead with the clinical or public health problem your technology addresses. Quantify the burden — patient populations affected, economic costs, mortality or morbidity data. Then identify the specific gap in current solutions that creates the opportunity for your innovation. The transition from problem to gap should feel inevitable: the current standard of care is inadequate because of X, and no existing technology addresses X because of Y.

Second paragraph: Your solution and why it works. Describe your innovation in concrete terms. What is it, how does it work at a high level, and what preliminary evidence do you have that it is feasible? If you have prototype data, animal study results, or a proof-of-concept demonstration, reference it here. Establish your team's credibility to execute — prior relevant SBIR awards, domain expertise, key patents, or clinical collaborations.

Specific Aims (2-3 for Phase I). Each aim should be a self-contained objective with a measurable milestone. For a Phase I, your aims should collectively answer the question: "Is this technology feasible enough to justify Phase II investment?" Frame aims around demonstrable outcomes:

• Aim 1: Develop and characterize [specific technical deliverable] — milestone: achieve [quantitative performance threshold]
• Aim 2: Validate [deliverable] in [relevant model system or clinical samples] — milestone: demonstrate [specific efficacy or accuracy metric]
• Aim 3 (if needed): Assess [regulatory, manufacturing, or clinical translation parameter] — milestone: generate [specific data package or deliverable]

Closing: Impact statement. Two to three sentences connecting successful Phase I completion to Phase II development and ultimately to clinical or commercial impact. This is where you briefly articulate the market opportunity and the path from feasibility data to a product that improves patient outcomes.

For a deep dive on Specific Aims structure, see the NIH Specific Aims guide.

NIH's Five Review Criteria and How Scoring Works

NIH SBIR applications are scored using the same five review criteria applied to all NIH research grants. Understanding what each criterion means in the SBIR context — and how scoring translates to funding decisions — is essential.

Significance (scored 1-9). Does this project address an important unmet medical need? Reviewers assess whether the health problem is significant, whether the proposed technology would meaningfully improve diagnosis, treatment, prevention, or research capability, and whether successful completion would have a measurable impact. For SBIR, significance also encompasses commercial significance — is there a real market for this technology, and will it reach patients?

Investigator (scored 1-9). Does the PI and project team have the qualifications to execute this work? Reviewers look at relevant technical expertise, prior SBIR track record (if any), scientific publications, patents, and the team's collective ability to cover all aspects of the proposed work. First-time SBIR applicants are not penalized per se, but you must demonstrate relevant domain expertise.

Innovation (scored 1-9). Does the proposed technology represent a meaningful advance over existing solutions? Novelty can come from a new mechanism of action, a new application of existing technology, a new manufacturing approach, or a new combination of known elements. Incremental improvements to existing products generally score poorly. Reviewers want to see a clear technical differentiator.

Approach (scored 1-9). Is the research plan well-designed, feasible within the Phase I scope, and likely to generate the data needed to evaluate feasibility? This is where reviewers scrutinize your experimental design, sample sizes, statistical plans, milestones, potential pitfalls, and alternative approaches. Overambitious Phase I plans — proposing two years of work in a twelve-month timeline — are a consistent source of poor Approach scores.

Environment (scored 1-9). Does the applicant have the facilities, equipment, and institutional support to perform the proposed work? For small businesses, this includes laboratory space, specialized equipment, manufacturing capabilities, and relationships with clinical sites or testing facilities. If you are subcontracting work to a university core facility or CRO, describe those arrangements specifically.

Each assigned reviewer scores all five criteria independently on a 1 (exceptional) to 9 (poor) scale. They then assign an Overall Impact Score that reflects their holistic assessment of the project's potential to advance biomedical innovation. The Overall Impact Score is not an average of the five criterion scores — a project with one weak area can still receive a strong impact score if the reviewers believe the overall contribution is significant.

After discussion, all eligible study section members vote on the Overall Impact Score. These scores are averaged and multiplied by 10 to produce a final impact score ranging from 10 (best) to 90 (worst). Scores are then converted to percentile rankings. Each IC sets a payline — the percentile cutoff below which applications are funded. Paylines vary by institute and fiscal year but typically fall between the 15th and 25th percentile. NCI and NIAID tend toward tighter paylines; smaller ICs can be more generous.

The Research Strategy: Six Pages That Determine Your Score

The Research Strategy is where you make the detailed scientific case for your project. NIH SBIR Phase I allows six pages for this section — the same limit as an R01 Research Strategy, though the content emphasis differs substantially.

Significance section (approximately 1-1.5 pages). Expand on the clinical or public health need you identified in your Specific Aims. Provide the epidemiological context, describe current standard of care and its limitations, and explain why existing technologies fail to solve the problem. Cite the literature, but be selective — every reference should directly support your argument for why this project matters. End with a clear statement of how your technology will change the current landscape if successful.

Innovation section (approximately 0.5-1 page). Articulate what is technically novel about your approach. Compare your technology directly to the closest existing solutions, using specific performance metrics where possible. If your innovation is a new biomarker, a new sensing modality, a new formulation approach, or a new algorithmic method, describe the underlying science that makes it possible. Intellectual property status — filed patents, provisional applications, trade secrets — belongs here.

Approach section (approximately 3-4 pages). This is the largest and most heavily scrutinized section. Structure it by Specific Aim.

For each aim, provide:

• Rationale: Why this aim is necessary and how it connects to the overall feasibility question
• Methods: Detailed experimental design, including materials, protocols, sample sizes, and statistical analysis plans
• Expected outcomes: What results would demonstrate success, with quantitative thresholds
• Potential pitfalls and alternatives: What could go wrong and how you will respond
• Timeline and milestones: When each deliverable will be completed within the project period

Preliminary data. NIH does not formally require preliminary data for Phase I, but competitive applications almost always include it. Even early-stage results — a proof-of-concept demonstration, benchtop prototype performance, computational simulations, or relevant published data from the PI's prior work — significantly strengthen the Approach section. Place preliminary data within the relevant aim's methods discussion, not as a separate section.

Rigor and reproducibility. NIH expects all applications to address scientific rigor. Describe your approach to experimental design rigor (randomization, blinding, controls), biological variables (sex, age, genetic background as relevant), authentication of key biological and chemical resources, and statistical power calculations.

A common Phase I mistake is overscoping. Reviewers know that $275,000 over twelve months limits what you can accomplish. Proposing three aims that each require a separate clinical study, a new manufacturing process, and a regulatory submission will damage your Approach score. Focus on the minimum set of experiments needed to demonstrate feasibility, and leave full development for Phase II.

Building a NIH-Specific Commercialization Plan

NIH has steadily increased the weight it places on commercialization potential in SBIR review. The Commercialization Plan is a required component of your application, and while it is not formally scored under the five review criteria, it directly influences reviewers' assessment of Significance and Overall Impact.

Market analysis. Define your target market in healthcare terms that reviewers — who are scientists, not MBAs — can evaluate. How many patients have the condition your technology addresses? What is the current cost of diagnosis or treatment? What are the reimbursement pathways? Use published epidemiological data and market research to size the opportunity. Avoid inflated total addressable market figures that lack clinical grounding.

Regulatory pathway. For any technology that will contact patients or generate clinical data, you must articulate your FDA strategy. Is your product a Class I, II, or III device? Will you pursue 510(k) clearance, De Novo classification, or PMA approval? For therapeutics, what is your IND strategy and clinical trial pathway? For diagnostics, will you seek CLIA waiver? Reviewers need confidence that you understand the regulatory landscape, even if the actual submissions are years away. If your technology does not require FDA clearance (research-use-only tools, computational platforms), state that explicitly.

Intellectual property. Describe your IP position: filed patents, provisional applications, freedom-to-operate analysis, and trade secrets. If your technology builds on university-licensed IP, explain the license terms and your commercial rights. NIH reviewers understand that early-stage companies may not have issued patents, but they want to see that you have a defensible IP strategy.

Commercialization trajectory. Map the path from Phase I results to market. What Phase II development work will be needed? What are the key technical and regulatory milestones between Phase II completion and first revenue? Who are your potential commercialization partners — strategic acquirers, distribution partners, or clinical adoption champions? If you have letters of support from potential customers, clinicians, or industry partners, reference them.

Revenue model. How will your company make money? Direct device sales, recurring consumables, software subscriptions, licensing fees, or contract manufacturing? NIH reviewers may not evaluate your financial projections rigorously, but they need to believe that a viable business model exists on the other side of successful R&D.

For a broader look at SBIR commercialization planning across agencies, see the complete SBIR application guide.

Budget and Administrative Requirements

NIH SBIR Phase I awards are capped at $275,000 in direct costs for most ICs, though some directed FOAs specify different limits. The budget format is modular — you request funds in $25,000 modules up to the cap, with a brief narrative justification for each budget category rather than line-item detail.

Key budget categories:

• Personnel: Salary and fringe benefits for the PI and all key personnel. The PI must commit sufficient effort to demonstrate leadership of the project — typically 20-40% for SBIR Phase I. Fringe rates should match your company's established rates or, if you lack an established rate, use a reasonable estimate based on your benefits package.
• Equipment: Items costing $5,000 or more per unit. Equipment purchases must be justified as essential to the proposed work and not available through other means.
• Supplies: Consumables, reagents, assay kits, software licenses, and other materials directly supporting the research.
• Travel: Conference attendance or travel to collaborator sites or clinical facilities. Keep travel budgets modest and directly tied to project needs.
• Subcontracts/Consortium: Work performed by universities, CROs, or other external partners. Remember the SBIR work percentage requirement: your company must perform at least two-thirds of the Phase I work (measured by cost). STTR requires the small business to perform at least 40% and the research institution at least 30%.

Administrative requirements. NIH SBIR applications are submitted through eRA Commons via Grants.gov. Your company must have an active SAM.gov registration, a DUNS/UEI number, and an eRA Commons account for the PI. The PI's Commons account must be affiliated with your company's organizational profile. Registration can take weeks, so start early.

Biosketches must follow the current NIH format (five pages per person). Use the SciENcv tool to generate compliant biosketches. Include relevant publications, prior SBIR awards, commercial products developed, and key personnel contributions.

From Phase I Results to Phase II

A successful Phase I is not an end point — it is the beginning of a much larger funding relationship with NIH. Your Phase I final report and the data you generate directly determine your competitiveness for Phase II.

What a compelling Phase I outcome looks like. You completed all proposed milestones or, if some aims yielded unexpected results, you can explain why those results still support the technology's feasibility. You generated quantitative data demonstrating that your technology meets or exceeds the performance thresholds you proposed. You identified and addressed key technical risks. And you have a clear, data-supported plan for Phase II development.

Phase II awards provide up to $1.75 million in direct costs over two years. The scope expands from feasibility to full prototype development, preclinical validation, manufacturing process development, and preparation for regulatory submissions. Phase II review uses the same five criteria but places greater emphasis on Phase I results, the strength of the commercialization plan, and the team's ability to execute a larger project.

Fast-Track applications combine Phase I and Phase II into a single submission. If funded, Phase II funding is contingent on successful Phase I completion — NIH reviews your Phase I progress before releasing Phase II funds. Fast-Track is appropriate when your technology is relatively mature, you have strong preliminary data, and you can present a credible integrated development plan. The review bar is higher because you are asking reviewers to commit to a larger investment based on pre-feasibility data.

Phase II Competing Renewal allows you to apply for a second Phase II award to continue development beyond the initial Phase II period. This is particularly relevant for technologies with long development timelines, such as therapeutics requiring clinical trials.

Commercialization Readiness Pilot (CRP). Several ICs offer supplemental funding between Phase II and commercialization, targeting activities like manufacturing scale-up, clinical trial preparation, and regulatory submissions. Check your IC's SBIR program page for available supplements.

For an overview of how SBIR reauthorization affects these pathways, see the SBIR reauthorization guide and the analysis of NIH SBIR changes after reauthorization.

Frequently Asked Questions

Can a biotech startup with no NIH track record win a Phase I? Yes. NIH explicitly welcomes new applicants. Your PI does not need prior NIH funding. However, you must demonstrate relevant technical expertise through publications, patents, industry experience, or prior product development. First-time applicants sometimes benefit from including a consultant or subcontractor with NIH experience on the team.

How do I find out which study section will review my application? The Center for Scientific Review (CSR) assigns applications to study sections based on the scientific content. You can use the CSR's Study Section Roster Index to browse active panels, or contact the SBIR program officer at your target IC — they can often predict the assignment. You may also request a specific study section in your cover letter, though CSR makes the final determination.

How long does the review process take? From submission to funding decision, expect approximately nine months. Applications submitted at a standard receipt date are reviewed at the next study section meeting (approximately four to five months later), and funding decisions follow one to two council cycles after that. Directed FOAs with special receipt dates may have different timelines.

Can I include human subjects research or clinical data collection in Phase I? Yes, but with important constraints. Any human subjects research requires IRB approval, and the protocol must be approved before NIH releases funds. Many Phase I applicants defer human subjects work to Phase II and use Phase I for benchtop feasibility, animal studies, or analysis of de-identified existing samples. If your Phase I requires human subjects, build the IRB timeline into your project plan.

What if my technology spans two institutes — for example, a cardiovascular AI diagnostic that uses neuroimaging? Indicate your preferred IC in the PHS 398 Cover Page Supplement, and explain your rationale in the cover letter. If the application could reasonably go to either IC, CSR may consult both program officers. Dual-assignment is possible but uncommon. The practical advice: contact both ICs' SBIR program officers before submitting and ask which one is the better fit.

Is preliminary data required for Phase I? Not formally required, but in practice, competitive applications include it. Even minimal data — computational modeling results, a benchtop proof-of-concept, or published work by the PI in the relevant domain — gives reviewers evidence that the proposed approach is grounded in reality rather than speculation.

What is the resubmission policy? You may submit one resubmission (A1) of an unfunded application. The resubmission must include a one-page Introduction that responds point-by-point to the reviewers' critiques from the summary statement. Resubmissions often score significantly better than initial submissions because you have a detailed roadmap of what the reviewers wanted to see.

Can I apply to both the Omnibus and a directed FOA simultaneously? You cannot submit the same project to both. However, you can submit different projects — one to the Omnibus and a distinct project to a directed FOA — in the same review cycle. If a directed FOA closely matches your technology, it is generally the stronger strategic choice because of dedicated funding and clearer alignment signals.

How do SBIR awards interact with venture capital funding? NIH does not prohibit VC-backed companies from receiving SBIR awards. However, majority VC ownership (more than 50%) triggers additional eligibility requirements under the SBIR/STTR Reauthorization Act. Your company must still meet the small business size standard, and the VC affiliation rules can be complex. If your company has taken institutional investment, review the SBA's affiliation guidance carefully or consult with your grants office.

What happens if Phase I results are negative? Negative results do not disqualify you from future NIH funding. If your Phase I demonstrates that the proposed approach is not feasible, report that finding honestly in your final report. You can still apply for Phase I funding for a different technology or a substantially modified approach. Reviewers respect intellectual honesty more than cherry-picked data.

---

NIH SBIR Phase I is among the most valuable funding mechanisms available to health technology startups — not just for the capital, but for the validation, the review feedback, and the pathway to Phase II and beyond. The companies that win consistently are the ones that treat the application as a scientific argument backed by commercial logic. If you are ready to build your NIH SBIR proposal, tools like Granted can help you move from initial concept to a submission-ready application before the next receipt date. You can also explore the general SBIR Phase 1 guide for cross-agency fundamentals, or browse live SBIR funding opportunities across all participating agencies.

For additional NIH SBIR strategy, read our analysis on aligning with NIH health research priorities and our guide to successful NIH SBIR resubmissions.